Preclinical studies with new pyrrolidine platinum(II) compounds

F. Sampedro; VWT W.T. Ruiz van Haperen; MA A. Izquierdo; M. Vicens; P. Santaló; M. Pueyo; M. Llagostera; E. Marcuello; L. De Andrés

doi:10.1016/0223-5234(96)88260-2

Preclinical studies with new pyrrolidine platinum(II) compounds

F. Sampedro, VWT W.T. Ruiz van Haperen, MA A. Izquierdo, M. Vicens, P. Santaló, M. Pueyo, M. Llagostera, E. Marcuello, L. De Andrés

Research output: Contribution to journal › Article › Research › peer-review

8 Citations (Scopus)

Abstract

Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.

Original language	English
Pages (from-to)	497-501
Journal	European Journal of Medicinal Chemistry
Volume	30
Issue number	6
DOIs	https://doi.org/10.1016/0223-5234(96)88260-2
Publication status	Published - 1 Jan 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

antitumoral activity
cancer treatment
growth
inhibition
L1210 leukemia
platinum(II) compound
platinum(II)-DNA damage
pyrrolidine
viability

Access to Document

10.1016/0223-5234(96)88260-2

Cite this

@article{ce6a315345904fea82d81dcd1f536985,

title = "Preclinical studies with new pyrrolidine platinum(II) compounds",

abstract = "Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. {\textcopyright} 1995 Elsevier, Paris.",

keywords = "antitumoral activity, cancer treatment, growth, inhibition, L1210 leukemia, platinum(II) compound, platinum(II)-DNA damage, pyrrolidine, viability",

author = "F. Sampedro and \{Ruiz van Haperen\}, \{VWT W.T.\} and Izquierdo, \{MA A.\} and M. Vicens and P. Santal{\'o} and M. Pueyo and M. Llagostera and E. Marcuello and Andr{\'e}s, \{L. De\}",

year = "1995",

month = jan,

day = "1",

doi = "10.1016/0223-5234(96)88260-2",

language = "English",

volume = "30",

pages = "497--501",

number = "6",

}

TY - JOUR

T1 - Preclinical studies with new pyrrolidine platinum(II) compounds

AU - Sampedro, F.

AU - Ruiz van Haperen, VWT W.T.

AU - Izquierdo, MA A.

AU - Vicens, M.

AU - Santaló, P.

AU - Pueyo, M.

AU - Llagostera, M.

AU - Marcuello, E.

AU - Andrés, L. De

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.

AB - Four new platinum compounds containing different pyrrolidines as ligands are reported. In vitro tests show damage to bacterial DNA and participation of RecA protein in the repair system. In vitro tests using leukemia L1210 cells show growth inhibition by the new compounds within the range of cisplatin and carboplatin. In vivo tests using leukemia L1210 cells on male BDF1 show that these compounds are significantly active. © 1995 Elsevier, Paris.

KW - antitumoral activity

KW - cancer treatment

KW - growth

KW - inhibition

KW - L1210 leukemia

KW - platinum(II) compound

KW - platinum(II)-DNA damage

KW - pyrrolidine

KW - viability

UR - https://www.scopus.com/pages/publications/0029043258

U2 - 10.1016/0223-5234(96)88260-2

DO - 10.1016/0223-5234(96)88260-2

M3 - Article

SN - 0223-5234

VL - 30

SP - 497

EP - 501

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

IS - 6

ER -

Preclinical studies with new pyrrolidine platinum(II) compounds

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this